An observational study in Fabry Disease and Fabry Disease, Cardiac Variant, sponsored by Sangamo Therapeutics. Active, not recruiting at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Sangamo Therapeutics · Observational
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
242 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
This study's enrollment of 32 is below the median of 100 across 123 observational studies indexed under Fabry Disease.
Browse Fabry Disease studies →Sangamo Therapeutics is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.
Exclusion Criteria:
-This study has no exclusion criteria
Subjects who received ST-920 in a separate parent trial
Biological: ST-920
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
To evaluate long-term safety of ST-920
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
Time frame: 4 years
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sangamo Therapeutics